Voices (Free subscription) | 01/10/2009
Akamai is losing deals in an attempt to hold the line on content deliver network pricing, according to Merriman Curhan Ford analyst Richard Fetyko, who late yesterday cut his rating on the stock to Sell from Hold.
Tech Trader Daily (Free subscription) | 01/10/2009
Akamai (AKAM) is losing deals in an attempt to hold the line on content deliver network pricing, according to Merriman Curhan Ford analyst Richard Fetyko, who late yesterday cut his rating on the stock to Sell from Hold. Fetyko asserts that Akamai’s CDN pricing “remains way out of line” - 30%-100% [...]
Detroit Free Press (Free subscription) | 01/10/2009
Ford Motor Co. today outlined the differences it sees between its labor contract with the UAW and the contracts the union reached last spring with General Motors Co. and Chrysler Group LLC.
Inside Redbox (Free subscription) | 03/11/2009
... kiosks had software installed that would allow variable pricing. Our old friend, Merriman Curhan Ford analyst Eric Wold , feels that even if higher rental prices became permanent, Redbox would not lose many customers. “I still believe consumers will view the value and convenience of Redbox for the immediate gratification of a DVD rental as superior to the other rental options out...
Inside Redbox (Free subscription) | 03/11/2009
... has the option to extend the program to 2014, with an out clause after two years.” Merriman Curhan Ford analyst and frequent Redbox commenter Eric Wold believes that Paramount will make its decision by the middle of December. Says Wold: “We believe investors will be watching for that decision closely given that Paramount will have a significant level of information on rental trends...
Bigthink - Site Features Feed (Free subscription) | 21/10/2009
America has a long and storied history with Ford Motor’s F-Series pickup truck. Sold in America for over 60 years the line of pickups hasn’t just been a longtime symbol of Americana and its iron-clad glory. It’s also been the country’s top-selling vehicle (not truck, vehicle) for 23 years and top-selling truck for 31 years. But with its U.S. market share shrinking...
Cinema Treasures (Free subscription) | 09/10/2009
... and AMC have locked up the majority of available markets in the U.S.," says Merriman Curhan Ford analyst Eric Wold. Read the whole article in USA Today .
Tech Trader Daily (Free subscription) | 01/10/2009
Shares of both Akamai (AKAM) and Limelight Networks (LLNW) are trading lower on increasing concerns about pricing in the content delivery network sector. As I previously noted, Merriman Curhan Ford analyst Richard Fetyko last night cut his rating on Akamai to Sell from Hold, asserting that AKAM is losing CDN business [...]
Seattle Times (Free subscription) | 01/10/2009
... who were taking a placebo, but the company said it is an encouraging result.Merriman Curhan Ford analyst Edward Nash said Catalyst addressed the reasons for the failure of the cocaine study, and he now thinks the company has a chance to develop vigabatrin successfully. He upgraded the shares to "Neutral" from "Sell.""We believe this creates a light at the end of the tunnel for Catalyst,"...
Star Tribune (Free subscription) | 01/10/2009
... who were taking a placebo, but the company said it is an encouraging result.Merriman Curhan Ford analyst Edward Nash said Catalyst addressed the reasons for the failure of the cocaine study, and he now thinks the company has a chance to develop vigabatrin successfully. He upgraded the shares to "Neutral" from "Sell."
San Fransisco Chronicle (Free subscription) | 01/10/2009
... who were taking a placebo, but the company said it is an encouraging result.Merriman Curhan Ford analyst Edward Nash said Catalyst addressed the reasons for the failure of the cocaine study, and he now thinks the company has a chance to develop vigabatrin successfully. He upgraded the shares to "Neutral" from "Sell.""We believe this creates a light at the end of the tunnel for Catalyst,"...
Seattle Post-Intelligencer (Free subscription) | 01/10/2009
... who were taking a placebo, but the company said it is an encouraging result.Merriman Curhan Ford analyst Edward Nash said Catalyst addressed the reasons for the failure of the cocaine study, and he now thinks the company has a chance to develop vigabatrin successfully. He upgraded the shares to "Neutral" from "Sell.""We believe this creates a light at the end of the tunnel for Catalyst,"...
kansascity.com (Free subscription) | 01/10/2009
... who were taking a placebo, but the company said it is an encouraging result.Merriman Curhan Ford analyst Edward Nash said Catalyst addressed the reasons for the failure of the cocaine study, and he now thinks the company has a chance to develop vigabatrin successfully. He upgraded the shares to "Neutral" from "Sell.""We believe this creates a light at the end of the tunnel for Catalyst,"...
